Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BRVE
Strong SellSinkerBraveheart Bio, Inc. · Healthcare · United States · $1.9B
11
StockRankGet insider-trade alerts
Q
37
V
25
M
24
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Loading 1Y...
PRICE (1Y)-8.6%
Close
$27.25
RSI (14)
49.2
SCORE BREAKDOWN
Quality
37
ROIC (ROA)
—N/A
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
—N/A
Piotroski
238.9
Int. Cover
—N/A
D/E Ratio
0.01x85.1
Current Ratio
8.11x83.8
Value
25
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
-10.4x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
24
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-6%19.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.9B
P/E (Forward)
-13.4x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BRVE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BRVE | Braveheart Bio, Inc.(you) | $1.9B | 11 | Strong Sell |
| KARD | Kardigan, Inc. | $1.9B | 11 | Strong Sell |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.1B | 11 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 11 | Strong Sell |
| KLRA | Kailera Therapeutics, Inc. | $2.1B | 11 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
| INBX | Inhibrx Biosciences, Inc. | $1.8B | 13 | Strong Sell |
| TSHA | Taysha Gene Therapies, Inc. | $1.9B | 13 | Strong Sell |
| ZBIO | Zenas BioPharma, Inc. | $2.0B | 14 | Strong Sell |
| KOD | Kodiak Sciences Inc. | $2.4B | 12 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%